We believe that Bleepa will accelerate the process of requesting a specialist opinion from colleagues, ultimately resulting in better care for patients, faster
Tom Oakley, chief executive
What Feedback does
The company’s products, TexRAD and CADRAN help radiologists, clinicians, and medical researchers improve their workflows as well as providing insights into diseases such as cancer.
The group has also launched a new clinical messaging app called Bleepa.
CADRAN is a system that helps users store, manage, and view medical images. It helps doctors access images for diagnosis, treatment planning, and response measurement as well as facilitating knowledge sharing between multi-disciplinary teams.
The CADRAN range consists of four products;
o CADRAN PACS – The Picture Archiving and Communication System (PACS) provides mid-scale departments with a network server, image viewer, and web interface to access images
o Mini PACS – A small-scale system for image storage and management using dedicated servers and workstations. Designed for smaller imaging clinics and remote workers
o Viewer+ – Displays medical images from imaging equipment using a standard desktop PC or laptop with measurement and analysis tools. Designed for convenience use and individuals
o CADRAN Web – allows remote access to images through a web-accessible image library. Can be viewed on desktop PC or laptop
TexRAD is a patented software tool that helps identify biomarkers (naturally occurring characteristics in diseases or other biological manifestations) in medical images that are often invisible to the naked eye.
The technology has a particular significance in oncology, the medical field concerned with the treatment of cancer.
The technology’s first clinical application is TexRAD Lung, which can help reveal information on lung tumours, whereas the other application, TexRAD Research, is used to complement existing infrastructure to help analyse medical image scans.
Bleepa is an encrypted medical messaging app that can be used on smartphones, tablets and desktops, allowing clinicians to communicate with other team members securely.
The app enables faster clinical decision making between team members, which will improve patient care.
How it is doing
In November, Feedback said its Bleepa product had been selected for DigitalHealth London’s 2020 12-month accelerator programme to promote innovative technologies to London National Health Service (NHS) hospitals.
The accelerator aims to speed up the adoption of technology within London’s NHS, relieving high pressure on services and empowering patients to manage their health.
In an AGM statement earlier that month, Feedback said it had a positive cash balance of GBP4.4mln as at the end of September 2020, which it will use to scale up its core product, Bleepa, a medical imaging communications app.
Much of the groundwork now complete, Feedback told investors, and the focus is to further grow Bleepa’s market base and create a strong platform for revenue growth. To aid this, the company recently strengthened its marketing team and hired an integration specialist in order to help increase the speed of roll-out.
In a separate announcement, Feedback revealed that Bleepa was been selected as a WISH 2020 Innovation Booster at the World Innovation Summit for Health (WISH) held in Doha, Qatar.
In October, the company said it was teaming up with Axial Medical Printing to add three-dimensional (3D) imaging to Feedback’s flagship Bleepa medical imaging communications platform.
Axial3D uses advanced artificial intelligence (AI) technologies to automatically create 3D reconstructions of individual organs or pathologies. These images will be available to view in the Bleepa platform and can subsequently be turned into 3D printed models in a variety of materials.
In August, Bleepa was awarded a place on the NHSx National Clinical Communication Tool (NCCT) framework, meaning NHS Trusts can buy it by drawing down from a GBP3mln centralised fund over two years, giving Bleepa national coverage and providing independent validation of the quality and suitability of the platform for frontline delivery.
Feedback said this stamp of approval will allow it to drive sales in other markets.
What the boss says: Tom Oakley, chief executive
Commenting on the DigitalHealth.London accelerator, Oakley said: “DigitalHealth.London is a targeted accelerator for London hospitals with a focus to scan the horizon for the very best of new innovative healthcare technologies, which it then showcases to London-based hospitals. It has an extremely rigorous selection process and we are delighted that Bleepa has been chosen as part of the 2020 offering.”
“For us, this is an important opportunity to really get in front of the London hospital network to show them what Bleepa can do, how it can revolutionise their imaging communications and ultimately, why they should choose Bleepa”, he added.